Mithra Pharmaceuticals SA

BATS-CHIXE:MITRAb Stock Report

Market Cap: €100.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mithra Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Mithra Pharmaceuticals's earnings have been declining at an average annual rate of -17.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 9% per year.

Key information

-17.7%

Earnings growth rate

-11.4%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate-9.0%
Return on equityn/a
Net Margin-125.8%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Mithra Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BATS-CHIXE:MITRAb Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2363-791769
31 Mar 2365-691766
31 Dec 2267-601764
30 Sep 2244-761670
30 Jun 2222-931676
31 Mar 2222-1051581
31 Dec 2123-1171485
30 Sep 2121-1151586
30 Jun 2119-1131687
31 Mar 2114-1031783
31 Dec 209-921778
30 Sep 2044-311771
30 Jun 2079291664
31 Mar 208811661
31 Dec 1997-271657
30 Sep 1984-541547
30 Jun 1971-821437
31 Mar 1964-551236
31 Dec 1858-281136
30 Sep 1846-411039
30 Jun 1833-531042
31 Mar 1833-461045
31 Dec 1732-381048
30 Sep 1726-371246
30 Jun 1720-361343
31 Mar 1721-361439
31 Dec 1622-351634
30 Sep 1621-291729
30 Jun 1620-231924
31 Mar 1620-161717
31 Dec 1520-10159
30 Sep 1519-9137
30 Jun 1518-8104
31 Mar 1519-5103
31 Dec 1419-3103
31 Dec 1318-281
31 Dec 1215-171

Quality Earnings: MITRAb is currently unprofitable.

Growing Profit Margin: MITRAb is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MITRAb is unprofitable, and losses have increased over the past 5 years at a rate of 17.7% per year.

Accelerating Growth: Unable to compare MITRAb's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MITRAb is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-41.9%).


Return on Equity

High ROE: MITRAb's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies